Trevi Therapeutics (TRVI) Tops Q2 EPS by 2c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Hyperscale Data acquires 48.5 acres to expand Michigan campus
• UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral